WallStSmart
CSTL

Castle Biosciences Inc

NASDAQ: CSTL · HEALTHCARE · DIAGNOSTICS & RESEARCH

$24.49
+1.03% today

Updated 2026-04-30

Market cap
$734.37M
P/E ratio
P/S ratio
2.13x
EPS (TTM)
$-0.83
Dividend yield
52W range
$15 – $44
Volume
0.4M

Castle Biosciences Inc (CSTL) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item201720182019202020212022202320242025
Revenue$13.75M$22.79M$51.87M$62.65M$94.08M$137.04M$219.79M$332.07M$344.23M
Revenue growth (YoY)+65.7%+127.6%+20.8%+50.2%+45.7%+60.4%+51.1%+3.7%
Cost of revenue$4.92M$5.30M$7.31M$9.69M$15.82M$32.01M$44.98M$60.20M$107.88M
Gross profit$8.83M$17.49M$44.55M$52.96M$78.26M$105.03M$174.81M$271.86M$236.35M
Gross margin64.2%76.8%85.9%84.5%83.2%76.6%79.5%81.9%68.7%
R&D$4.47M$4.85M$7.38M$13.26M$29.65M$44.90M$53.62M$52.04M$51.85M
SG&A$15.26M$16.47M$29.84M$48.13M$86.74M$56.40M$66.50M$76.58M$229.32M
Operating income$-10.90M$-3.84M$7.33M$-6.54M$-40.08M$-72.86M$-67.98M$8.67M$-42.81M
Operating margin-79.2%-16.8%14.1%-10.4%-42.6%-53.2%-30.9%2.6%-12.4%
EBITDA$-10.40M$-3.76M$10.28M$-7.09M$-36.60M$-58.34M$-45.02M$38.14M$11.34M
EBITDA margin-75.6%-16.5%19.8%-11.3%-38.9%-42.6%-20.5%11.5%3.3%
EBIT$-10.71M$-4.08M$9.92M$-7.57M$-40.01M$-68.89M$-57.35M$22.14M$-29.43M
Interest expense$1.65M$2.27M$4.57M$2.63M$1000.00$17000.00$11000.00$577000.00$86000.00
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-12.37M$-6.37M$5.28M$-10.28M$-31.29M$-67.14M$-57.47M$18.25M$-24.16M
Net income growth (YoY)+48.5%+182.9%-294.9%-204.3%-114.6%+14.4%+131.7%-232.4%
Profit margin-89.9%-27.9%10.2%-16.4%-33.3%-49.0%-26.1%5.5%-7.0%